Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kjemoterapiindusert kognitiv svikt (CONCERT)

11. november 2026 oppdatert av: University of Aberdeen

Inflammatoriske og nevrale korrelater av kjemoterapi-indusert kognitiv svikt: en pilotstudie

Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is often based on comments of breast cancer patients attending outpatient clinics during and after their chemotherapy. Changes in thinking ability like lack of concentration, loss of memory and the inability to hold a thought or even a conversation has a significant impact on the lives of breast cancer patients. Without understanding what "chemobrain" is, and what causes it, there is little that doctors can do to help at the moment.

The team proposing this study believe that chemotherapy causes chemicals associated with inflammation to attack parts of the brain that are important for concentration and making new memories. Unfortunately, it is not possible to measure these chemicals directly in the brain, but we believe that a brain scan sensitive to excess iron, a marker of brain inflammation, can help. This project will measure thinking ability, such as memory and concentration, take a blood sample and do a brain scan before, during and after a patient has chemotherapy. We will then look for changes in iron in the brain areas that are important for concentration and memory and compare those to changes in thinking ability and to levels of inflammation chemicals in the blood. This information will be essential to help plan our next step which is to test ways to reduce the effects of "chemobrain".

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Ten critical research gaps and translational priorities in breast cancer were identified and published in 2013. One of them (#9) highlighted the need of developing interventions and support to improve the survivorship experience. It is well known that cancer treatment can cause significant long-term effects on a patient's life. Cognitive dysfunction has been recognised as one of those negative effects. The majority of breast cancer patients are living significantly beyond their breast cancer diagnosis. Most of the patients receiving chemotherapy are deemed to be at performance status '0'; fully participating in society, fully active with no restrictions on any activities prior to their cancer diagnosis. These patients are treated with curative intent. It is anticipated for them to fully integrate and return to their everyday life after their breast cancer treatment has been completed. However, for some this is not the case.

Many side effects of chemotherapy, such as fatigue or immune suppression, are well-known but it is less recognised that chemotherapy can cause long-term changes in concentration, memory and learning. This has been referred to as "chemofog". Recent studies suggest that about 15-45% of patients complain about memory and attention problems, lack of concentration, and deficits in multitasking or decision-making following chemotherapy. A number of possible explanations have been proposed for these changes, one is that many chemotherapy drugs are designed to stop cell division. An important part of normal brain function is neurogenesis, the process of creating new neurons, the building blocks of the brain. If cell division is stopped these building blocks can no longer be produced. The hippocampus and striatum are areas critically important to many brain functions. If new neurons are not made, the hippocampus shrinks which is a marker of the memory problems associated with dementia. As well as reducing neurogenesis, chemotherapeutic drugs can also change the balance of important chemicals in the brain called neurotransmitters. This can lead to decreased focus, arousal, and thinking speed. Finally, chemotherapeutic drugs can induce inflammation which can maintain these deficits for years after treatments cease.

Fifty patients will be recruited who have been diagnosed with breast cancer and are having either neoadjuvant or adjuvant chemotherapy as part of their treatment. They will attend the University of Aberdeen research MRI facility on 3 occasions: 1) within 2 weeks of diagnosis, 2) 4 weeks after the last cycle of chemotherapy, 3) 6 months following the end of chemotherapy. Patients on the most common treatment, anthracyclines with or without taxane, will be the focus of this study. A baseline scan before chemotherapy means each patient will be their own control.

During each visit the following will take place:

Brain magnetic resonance imaging: Brain MRI will be performed using a Philips Ingenia dStream 3T scanner and a 32-channel phase-array head coil. The protocol will include structural images (3D T1-weighted, 3D T2-weighted, 3D susceptibility weighted imaging (SWI), fluid attenuated inversion recovery (FLAIR), resting state fMRI (rs-fMRI) and diffusion tensor imaging (DTI). These sequences will allow us measure regional brain volumes and brain functional connectivity and also to see clinically significant features.

Cognitive and general health assessments: 5 individual components of general intelligence, cognitive fatigue, a potential confounder in cognitive testing, depression and anxiety and general health:

  1. Digit Symbol Coding to measure information processing speed

  2. Mill Hill Vocabulary test used as a measure of acquired verbal intelligence and an estimate of peak cognitive ability

  3. Controlled Oral Word Association task used as a measure of verbal fluency

  4. The Logical Memory test used to assess

    1. immediate declarative recall
    2. delayed declarative recall (30 min. apart)
  5. Matrix Reasoning test, assessing perceptual organisation and visuospatial logic

  6. Chalder Fatigue Scale

  7. Hospital Anxiety and Depression Scale

  8. General Health Questionnaire Blood sample collection: Blood samples will be collected at the time of imaging and cognitive testing to allow high sensitivity ELISA (Enzyme-Linked Immunosorbent Assay) tests for plasma levels of inflammation markers: Total body iron index (sTfR and Ferritin), IL-6, TNF-alpha, IL-1beta, Glutathione Peroxidase-3 (GPX3) activity, Colony-stimulating factor 1 (CSF-1), high-sensitivity c-reactive protein (hsCRP) and F2-isoprostane, a systemic marker of oxidative stress that reflects lipid peroxidation levels. A full blood count will be performed to screen for clinically significant levels of anaemia and immune cell counts.

Studietype

Observasjonsmessig

Registrering (Antatt)

50

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Aberdeen, Storbritannia
        • Rekruttering
        • NHS Grampian
        • Ta kontakt med:
          • Victoria Murdoch, MBChB
        • Hovedetterforsker:
          • Gordon D Waiter, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients diagnosed with Breast Cancer who have been prescribed adjuvant or neo-adjuvant chemotherapy

Beskrivelse

Inclusion Criteria:

  • Women and men >18 years
  • Diagnosed with HER2 negative breast cancer
  • Receiving EC-Taxane or Taxane only based chemotherapy
  • Able to communicate in English
  • Willing and able to give informed consent for participation in the study.

Exclusion Criteria:

  • Any patient whose physical condition will preclude them from lying still for the duration of the brain scan.
  • pre-excisting mental condition/disability
  • Contraindication to magnetic resonance scanning such as an implantable cardiac device.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Patient

No intervention

Observation only

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive performance late post chemotherapy
Tidsramme: 6 months

General intelligence will be determined with PCA from 5 separate tests to give 'g' general intelligence.

'g' is scaled to have a mean of 100 and a standard deviation of 15 giving an IQ-like measure of general intelligence.

6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. desember 2022

Primær fullføring (Faktiske)

9. november 2026

Studiet fullført (Antatt)

9. desember 2026

Datoer for studieregistrering

Først innsendt

7. februar 2023

Først innsendt som oppfylte QC-kriteriene

22. februar 2023

Først lagt ut (Faktiske)

23. februar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. mars 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2-028-22

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere